By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: 3 Out Of 4 People With Symptomatic Asthma Report Reduced Productivity At Work 5/26/2016 10:53:08 AM
Boehringer Ingelheim Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn’s Disease 5/24/2016 9:59:16 AM
Boehringer Ingelheim, BioMed X Establish Team of Scientists to Discover New Treatments for Psychiatric Diseases 5/23/2016 6:20:32 AM
Boehringer Ingelheim Launches "Conoce a Don Francisco" Sweepstakes 5/19/2016 10:58:46 AM
Boehringer Ingelheim Release: South Korea Is First To Approve Next Generation Lung Cancer Treatment Olmutinib (BI 1482694 / HM61713) 5/17/2016 11:15:41 AM
Boehringer Ingelheim Release: New Presentations At American Thoracic Society 2016 Reinforce OFEV (Nintedanib) Efficacy, Safety And Tolerability Across Range Of Patients With IPF 5/16/2016 8:24:25 AM
Boehringer Ingelheim: Nine Out Of 10 AF Patients Are Concerned About Stroke And Many Want To Be Part Of OAC Treatment Decisions, New International Survey Shows 5/11/2016 11:07:39 AM
Boehringer Ingelheim Release: Pradaxa: First NOAC To Be Assessed In Prospective Study In Patients With Blood Clots In The Veins Or Venous Sinuses Of The Brain 5/11/2016 10:56:45 AM
Lead Discovery Center And Boehringer Ingelheim Join Forces to Discover A Novel Approach For The Treatment Of Schizophrenia 5/11/2016 9:20:46 AM
LUME-Meso Trial Enrolls First Patient: Boehringer Ingelheim’s New Pivotal Study Investigating Nintedanib For The Treatment Of Malignant Pleural Mesothelioma 5/9/2016 11:23:03 AM